Home / Business and Economy / FDA Proposes New Rule for Drug Manufacturing
FDA Proposes New Rule for Drug Manufacturing
10 Jul
Summary
- FDA proposed a new rule to streamline drug manufacturing site registration.
- The rule clarifies reporting for foreign production facilities.
- It aims to improve transparency in the drug supply chain.
The U.S. Food and Drug Administration (FDA) has initiated a new rule proposal aimed at enhancing transparency in the drug supply chain. This regulatory update focuses on streamlining the registration process for specific drug manufacturing sites.
If finalized, the proposed rule would permit manufacturers employing a 'hub-and-spoke' operational model to register their facilities as a single entity. This model involves a central site overseeing quality control across multiple production units located in different areas.
Furthermore, the proposal seeks to clarify the reporting requirements for foreign production facilities. These efforts collectively aim to create a more transparent and efficient drug manufacturing and distribution network.
